-
2022-502155-65-00
5
2024-07-30
Extra pulmonary sarcoidosis
-
2023-509905-62-00
5
2024-07-19
Lower limb trauma requiring immobilisation
-
2024-514107-34-00
4
2024-07-18
BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER
-
2022-500013-32-01
5
2024-07-05
Adrenocortical carcinoma
-
2023-505112-38-00
11
2024-07-01
recently active non-infectious intermediate, posterior, and pan-uveiti
-
2023-504514-29-00
1
2024-06-18
Gastroesophageal Junction (GEJ) Adenocarcinoma
-
2023-503606-36-00
9
2024-06-17
Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ o
-
2023-504251-27-00
7
2024-05-27
Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mut
-
2023-506282-66-00
5
2024-05-27
Women with ER+ HER2- metastatic breast cancer who progressed on first
-
2023-505929-14-00
5
2024-05-21
Systemic Lupus Erythematosus
-
2023-503631-18-01
5
2024-05-20
Nervous system diseases
-
2023-504151-27-00
5
2024-05-09
Psychosis associated with Alzheimer’s Disease
-
2023-503645-63-00
5
2024-04-25
Patients aged 65 years or older, hospitalized in a non-ICU ward for a
-
2024-513371-41-00
4
2024-04-25
Severe uveitis of Behçet’s disease
-
2023-503317-29-00
5
2024-04-12
Metastatic renal cell carcinoma (mRCC)
-
2024-516150-22-00
4
2024-04-11
HIV
-
2022-500879-31-00
3
2024-04-09
obesity
-
2023-503412-33-00
5
2024-03-29
Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
-
2022-501554-11-00
4
2024-03-21
Patients with previously untreated Richter’s syndrome (RS), defined as
-
2023-504472-24-00
4
2024-03-19
Early Idiopathic Parkinson’s disease (PD)
-
2023-506330-73-00
5
2024-03-13
Advanced (unresectable or metastatic)
human epidermal growth receptor
-
2023-507441-29-00
5
2024-02-29
Pneumonia
-
2022-501453-36-00
5
2024-02-23
Breast cancer
-
2023-504863-17-00
5
2024-02-21
1. Lupus Erythematosus, Cutaneous, Subacute
2. Chronic Cutaneous Lupus